XenoTherapeutics to Acquire Repare Therapeutics in $78.2 Million Deal

In a significant move within the pharmaceutical industry, precision oncology company Repare Therapeutics has agreed to be acquired by XenoTherapeutics, a nonprofit biotech organization focused on regenerative medicine. The deal, announced on November 14, 2025, values Repare at $1.82 per share, totaling approximately $78.2 million based on the company's outstanding shares as of September 30.

Deal Structure and Financial Details

The acquisition includes a contingent value right (CVR) for Repare shareholders, offering potential additional compensation tied to the success of Repare's existing partnerships with Bristol Myers Squibb, Debiopharm, and DCx Biotherapeutics. This structure provides an opportunity for investors to benefit from future milestone achievements and royalties.

Steve Forte, Repare's president, CEO, and chief financial officer, stated, "Following a thorough and wide-ranging strategic review of potential opportunities, partnerships and transactions aimed at maximizing shareholder value, Repare's board of directors has unanimously determined that the transaction is in the best interests of Repare and its various stakeholders."

Repare's Pipeline and Recent Challenges

Repare Therapeutics, headquartered in Massachusetts and Montreal, has faced significant challenges in recent years. The company's pipeline includes several promising oncology candidates:

1. RP-3467: An ATPase inhibitor currently in phase 1 trials
2. RP-1664: A PLK4 inhibitor also in phase 1 trials
3. Camonsertib (RP-3500): An ATR inhibitor that completed a phase 1/2 study in June 2025

Despite these assets, Repare has undergone substantial restructuring. In August 2024, the company reduced its workforce by 25% and narrowed its research focus. Early 2025 saw further cuts, with 75% of employees, including Chief Medical Officer Maria Koehler, M.D., Ph.D., being let go. Additionally, Repare halted plans for a phase 3 trial of camonsertib in combination with PKMYT1 inhibitor lunresertib.

In a cost-saving measure, Repare offloaded lunresertib to Debiopharm for $10 million upfront in July 2025. The company will continue its efforts to out-license its remaining programs until the acquisition closes, expected in the first quarter of 2026.

XenoTherapeutics' Expansion in Biotech

XenoTherapeutics, a Massachusetts-based nonprofit research foundation, has been actively expanding its presence in the biotech sector. The acquisition of Repare follows its earlier purchase of Essa Pharma in July 2025. Both deals were backed by Xoma Royalty, a company specializing in acquiring struggling biotechs.

XenoTherapeutics' primary focus is on developing regenerative medicines using genetically engineered pigs. This acquisition of Repare Therapeutics represents a significant expansion of their portfolio into precision oncology, potentially creating synergies between their existing regenerative medicine programs and Repare's oncology pipeline.